Targeting of the AKT/m-TOR Pathway: Biomarkers of Resistance to Cancer Therapy-- AKT/m-TOR Pathway and Resistance to Cancer Therapy

Zhongguo Fei Ai Za Zhi. 2018 Jan 20;21(1):63-66. doi: 10.3779/j.issn.1009-3419.2018.01.09.

Abstract

Resistance to cancer therapy continues to be a major limitation for the successful treatment of cancer. There are many published studies on therapy resistance in breast and prostate cancers; however, there are currently no data on molecular markers associated with resistance. The conflicting data were reported regarding the AKT/m-TOR signaling pathway components as markers predicting resistance. The AKT/m-TOR signaling pathway is involved in the development of many human cancers; its activation is related to cell proliferation, angiogenesis, apoptosis, as well as to therapy resistance. Molecular alterations in the AKT/m-TOR signaling pathway provide a platform to identify universal markers associated with the development of resistance to cancer therapy.

Keywords: AKT/m-TOR signaling pathway; Molecular markers; Resistance to cancer therapy.

Publication types

  • Review

MeSH terms

  • Animals
  • Biomarkers, Tumor / metabolism*
  • Drug Resistance, Neoplasm*
  • Humans
  • Molecular Targeted Therapy / methods*
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism
  • Neoplasms / pathology
  • Proto-Oncogene Proteins c-akt / metabolism*
  • Signal Transduction / drug effects*
  • TOR Serine-Threonine Kinases / metabolism*

Substances

  • Biomarkers, Tumor
  • Proto-Oncogene Proteins c-akt
  • TOR Serine-Threonine Kinases